always online......
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
03/18/16 Positive Cannabinoid Testing Data in California Prompts
Tweets by ?@CannabisScienc1 https://twitter.com/CannabisScienc1?ref_src=twsrc%5Etfw
Cannabis Science ?@CannabisScienc1
Cannabis Science CEO Unveils Loyalty Gift Procedure at 12:00 NOON PDT and ... http://goo.gl/eUGTLh
51m
Cannabis Science ?@CannabisScienc1
Cannabis Science is Excited as the DEA Considers to Reschedule Cannabis With Decision as Early as Mid-Year, 2016 http://goo.gl/3aFR1Z
06 Apr
Cannabis Science ?@CannabisScienc1
The Cannabis Science 360,000 Sq. Ft., Drug Development Compound Educational, Medical Facilities, and Laboratory... http://goo.gl/gYXTYD
04 Apr
Cannabis Science ?@CannabisScienc1
#Cannabinoids found in #Marijuana are also found in #humanbreastmilk. #cannabisfacts
View image on Twitter
View image on Twitter
01 Apr
Cannabis Science ?@CannabisScienc1
Cannabis Science CEO Excited as Record Date for Gifted Shares Approaches Tomorrow, Thursday, March 31st, 2016... http://goo.gl/OaZDoz
30 Mar
Cannabis Science ?@CannabisScienc1
Cannabis Science Negotiates a Total 360,000 Sq. Ft. Licensed Cannabinoid Grow and Formulation Processing in Nevada.. http://goo.gl/CjSBiF
24 Mar
Cannabis Science ?@CannabisScienc1
#CannabisforAutism #Shareyourstory http://www.cbisrf.org/pac #autismawareness #medicalmarijuana
View image on Twitter
View image on Twitter
17 Mar
Cannabis Science ?@CannabisScienc1
Join the #CannabisScience #PatientAccessCenter http://www.cbisrf.org/pac #shareyourstory
View image on Twitter
View image on Twitter
15 Mar
Cannabis Science ?@CannabisScienc1
Cannabis Science Moves Forward Clinical Drug Development With Confidence as GWPharma Announces Positive Results..
http://goo.gl/8oQceU
14 Mar
Cannabis Science ?@CannabisScienc1
CBIS CEO Plans to Expand Share Gifts to ALL Shareholders up to March 31, 2016, Thus Including ALL Old & New ... http://mwne.ws/1LgUKTE
11 Mar
Cannabis Science ?@CannabisScienc1
OmniCanna Health Solutions Inc. Proudly Announces the Showcasing of the Company's Flagship Brand -- 'The Hempery' http://mwne.ws/1nwktff
09 Mar
Cannabis Science ?@CannabisScienc1
In an Unprecedented Move, Cannabis Science President & CEO, Mr. Raymond C. Dabney, to Gift His Personal ... http://mwne.ws/1TYd9FW
04 Mar
Cannabis Science ?@CannabisScienc1
Cannabis Science News for March 4, 2016 - http://mwne.ws/1TYd9FW
04 Mar
Cannabis Science ?@CannabisScienc1
CBIS Set to Partner and Power the New iPhone APP, "The Joey Network", Just Released by Mieko Hester-Perez...
http://tinyurl.com/hgv7qa2
01 Mar
Cannabis Science ?@CannabisScienc1
Cannabis Science, Inc. (CBIS) Continues to Support CNN's Dr. Sanjay Gupta for His Ongoing Efforts to Educate...
http://mwne.ws/1SciJoh
29 Feb
Cannabis Science ?@CannabisScienc1
#cannabisscience ?????? #cannabis #medicalmarijuana #thc #cbd
Tag a #patient or #dispensary that would need this ????????
View image on Twitter
View image on Twitter
26 Feb
Cannabis Science ?@CannabisScienc1
http://www.marketwired.com/press-release/purple-haze-properties-php-cannabis-science-cbis-announce-successful-launch-hendrix-otc-pink-cbis-2099855.htm …
24 Feb
Cannabis Science ?@CannabisScienc1
Check out Jimi's Meds! #cbd #painrelief #lotion http://www.purplehazeproperties.com
View image on Twitter
View image on Twitter
23 Feb
Cannabis Science ?@CannabisScienc1
Check out "Jimi's Genetix" strains and concentrates !!! http://www.purplehazeproperties.com #cannabis #cannabisscience
View image on Twitter
View image on Twitter
Cannabis Science ?@CannabisScienc1
#MedicalMarijuana may help treat #PTSD. What are your thoughts?
View image on Twitter
View image on Twitter
16 Feb
Embed
-04/11/16 -Cannabis Science CEO Unveils Loyalty Gift Procedure at 12:00 NOON PDT and Releases Development Updates on the 360,000 Sq. Ft. Nevada Research Complex Including University, Cultivation Centers, Formulation Laboratory, and Medical Clinic
COLORADO SPRINGS, CO -- (Marketwired) -- 04/11/16 -- Cannabis Science, Inc. (OTC PINK: CBIS), a U.S. company specializing in the development of cannabis-based medicines, today CEO Raymond C. Dabney releases the "Loyalty Gift" procedure on the CBIS website at NOON, Pacific Today. The website will allow individuals to login and submit information and documentation to receive their "Loyalty Gift" directly from Mr. Dabney's personal holdings.
The Company has just received the first schematics renderings of the 360,000 Sq. Ft. Nevada Compound. The property development project and projected build outs will be further vetted out to include detailed land parcel assignments and proposed University and medical complex renderings. The Company has received serious requests expressing interest in the development complex and the Company has been speaking with several individuals/entities interested in participating in the development process. The released renderings will include parcel allocation and the company is very pleased with the rapid projected progress to fill these parcels, as it is talking with interested parties daily. Once the final plans are ready for public viewing, the Company will release the full property details along with the completed renderings and land plot assignments for the University, medical facility, cultivation centers, and Laboratory.
"This is a very special time and I want to extend my personal 'Thanks' to everyone who has supported me throughout the years. I have been blessed with 'Very Loyal People' who have supported me for years on end. I will recognize your names, and I look forward to reconnecting with many of you via phone. I have lost contact with some of you and you know who you are, I will be reaching out to you as well. Each of you are included in this 'Personal Thank You Gift', whether you own CBIS Shares or not. Again Thank YOU All, for your confidence, your support, and your Loyalty throughout the years. For this Loyalty I will be 'Giving you some of my personal shares' of Cannabis Science Inc. This is my personal confirmation of my Appreciation of you and your Loyalty. To the CBIS shareholders that I will 'Gift some of my Shares', I want and expect nothing in return, as a matter of fact, in the future everyone can look forward to 'more Loyalty Gifts' as we progress forward with our High-Growth Business Models in our group of Companies," stated Mr. Raymond C. Dabney, President, CEO, & Co-Founder of Cannabis Science Inc.
About Cannabis Science, Inc.
Cannabis Science, Inc., takes advantage of its unique understanding of metabolic processes to provide novel treatment approaches to a number of illnesses for which current treatments and understanding remain unsatisfactory. Cannabinoids have an extensive history dating back thousands of years, and currently, there are a growing number of peer-reviewed scientific publications that document the underlying biochemical pathways that cannabinoids modulate. The Company works with leading experts in drug development, medicinal characterization, and clinical research to develop, produce, and commercialize novel therapeutic approaches for the treatment for illnesses caused by infections as well as for age-related illness. Our initial focus is on skin cancers, HIV/AIDS, and neurological conditions. The Company is proceeding with the research and development of its proprietary drugs as a part of this initial focus: CS-S/BCC-1, CS-TATI-1, and CS-NEURO-1, respectively.
Forward-Looking Statements
This Press Release includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Act of 1934. A statement containing words such as "anticipate," "seek," intend," "believe," "estimate," "expect," "project," "plan," or similar phrases may be deemed "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Some or all of the events or results anticipated by these forward-looking statements may not occur. Factors that could cause or contribute to such differences include the future U.S. and global economies, the impact of competition, and the Company's reliance on existing regulations regarding the use and development of cannabis-based drugs. Cannabis Science, Inc., does not undertake any duty nor does it intend to update the results of these forward-looking statements. Safe Harbor Statement. The Private Securities Litigation Reform Act of 1995 provides a 'safe harbor' for forward looking statements. Certain of the statements contained herein, which are not historical facts are forward looking statements with respect to events, the occurrence of which involved risks and uncertainties. These forward-looking statements may be impacted, either positively or negatively, by various factors. Information concerning potential factors that could affect the company are detailed from time to time in the company's reports filed with the Securities and Exchange Commission.
Cannabis Science, Inc.
Investor Relations
Teresa Misenheimer
teresa@cannabisscience.com
Tel: 1-888-263-0832
Cannabis Science, Inc.
Mr. Raymond C. Dabney
Director, President & CEO, Co-Founder
raymond.dabney@cannabisscience.com
Tel:1-888-263-0832
Cannabis Science, Inc.
Mr. Robert Kane
Director & CFO
info@cannabisscience.com
Tel: 1-888-263-0832
Source: Cannabis Science, Inc.
Cannabis Science Is Very Excited as the DEA Considers to Reschedule Marijuana/Cannabis With a Landmark Decision as Early as Mid-Year, 2016
COLORADO SPRINGS, CO--(Marketwired - Apr 6, 2016) - Cannabis Science, Inc. (OTC PINK: CBIS), a U.S. company specializing in the development of cannabis-based medicines, today acknowledges and is very excited about the Landmark move with the Drug Enforcement Agency's (DEA) decision to review marijuana's federal drug classification as early as mid-2016. Rescheduling marijuana would ease restrictions on research across the country, while at the same time reducing penalties for marijuana offenses. Increased research capabilities could spur innovation and growth in the cannabis industry.
To review the Huffington Post article please click here to read the article in its entirety.
In a letter to the Senators; http://big.assets.huffingtonpost.com/dearesponse.pdf the Drug Enforcement Administration (DEA) is looking to decide on the reclassification of Marijuana by mid-year.
For years, marijuana has shared the "Schedule I" classification with heroin and LSD, drugs with much higher rates of death and hospitalization for users. This classification also specifies the drug has no "current accepted medical use". Cannabis Science, along with the masses, believe this has changed emphatically, based on the many ground-breaking university and private studies along with the ever growing long list of peer reviewed articles.
"We are very pleased to hear the DEA's decision to review marijuana's drug classification scheduling. It is clear to us and to so many others that the natural drug offers a host of health benefits and treatment properties. Cannabis Science will benefit extraordinarily as our research is already on the cutting edge, this Landmark move will open the industry in leaps and bounds," said Cannabis Science Inc. President, CEO & Co-Founder Raymond C. Dabney.
The DEA hopes to publish its decision in the first half of 2016. This decision is becoming increasingly important as more states decide to legalize cannabis for medicinal use. Nearly half of the U.S. states have already made such a decision, and a schedule change would have positive benefits for each of them.
About Cannabis Science, Inc.
Cannabis Science, Inc., takes advantage of its unique understanding of metabolic processes to provide novel treatment approaches to a number of illnesses for which current treatments and understanding remain unsatisfactory. Cannabinoids have an extensive history dating back thousands of years, and currently, there are a growing number of peer-reviewed scientific publications that document the underlying biochemical pathways that cannabinoids modulate. The Company works with leading experts in drug development, medicinal characterization, and clinical research to develop, produce, and commercialize novel therapeutic approaches for the treatment for illnesses caused by infections as well as for age-related illness. Our initial focus is on skin cancers, HIV/AIDS, and neurological conditions. The Company is proceeding with the research and development of its proprietary drugs as a part of this initial focus: CS-S/BCC-1, CS-TATI-1, and CS-NEURO-1, respectively.
Forward-Looking Statements
This Press Release includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Act of 1934. A statement containing words such as "anticipate," "seek," intend," "believe," "estimate," "expect," "project," "plan," or similar phrases may be deemed "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Some or all of the events or results anticipated by these forward-looking statements may not occur. Factors that could cause or contribute to such differences include the future U.S. and global economies, the impact of competition, and the Company's reliance on existing regulations regarding the use and development of cannabis-based drugs. Cannabis Science, Inc., does not undertake any duty nor does it intend to update the results of these forward-looking statements. Safe Harbor Statement. The Private Securities Litigation Reform Act of 1995 provides a 'safe harbor' for forward looking statements. Certain of the statements contained herein, which are not historical facts are forward looking statements with respect to events, the occurrence of which involved risks and uncertainties. These forward- looking statements may be impacted, either positively or negatively, by various factors. Information concerning potential factors that could affect the company are detailed from time to time in the company's reports filed with the Securities and Exchange Commission.
CONTACT INFORMATION
Cannabis Science Inc.
Teresa Misenheimer
Investor Relations
teresa@cannabisscience.com
Tel: 1-888-263-0832
Cannabis Science, Inc.
Mr. Raymond C. Dabney
President & CEO, Co-Founder
raymond.dabney@cannabisscience.com
Tel: 1-888-263-0832
Cannabis Science, Inc.
Mr. Robert Kane
Director & CFO
info@cannabisscience.com
Tel: 1-888-263-0832
03/18/16 Positive Cannabinoid Testing Data in California Prompts Cannabis Science Lab Expansions for IGXBio's GenePro FDA Investigational New Drug (IND) Number 015982 for Further Drug Development to Identify & Develop Agonist Cannabinoids for GenePro
LOS ANGELES, CA -- (Marketwired) -- 03/18/16 -- Cannabis Science, Inc. (OTC PINK: CBIS), a U.S. company specializing in the development of cannabis-based medicines announces that it is expanding its California clinical drug development operations to work with its partner IGXBio, Inc. in developing effective therapeutics using IGXBio's Immuonotherapy (GenePro®, also referred to as ?4SHIVKU2) FDA Investigational New Drug (IND). Number 015982.
GenePro® is an investigational DNA immunotherapy sponsored by IGXBio and would be considered a biologic. The Cannabis Science partnership is working to identify and develop agonist cannabinoids and IGXBio's GenePro®.
GenePro® is a deoxyribonucleic acid (DNA) plasmid vaccine expressing simian immunodeficiency virus (SIV) and human immunodeficiency virus (HIV) proteins, which is administered by electroporation (EP). This FDA IND supports a biologic and device combination product.
HIV uses our immune system to infect healthy immunogenic cells and increase the opportunity of these cells to spread. HIV-1 proteins (gp120, Tat -- the transactivator of transcription, Vpr, and Nef) are released from infected cells throughout the course of infection and create an ongoing HIV disease burden in a number of tissues, including the central nervous system (CNS), resulting in toxicity and damage, regardless of ART.
A substantial number of individuals with HIV disease suffer brain impairment such as HIV-1 associated cognitive impairment (HAND) and dementia. Many standard anti-retroviral drugs cannot cross the blood-brain barrier (BBB) and therefore they have no effect on HIV infection in the brain.
"To further cement our foothold in the substantial pharmaceutical drug development industry, we expect our IGXBio, GenePro® drug development program to be a major pharmaceutical success. Program specific details are underway and we will update progress and results as they come in," stated Dr. Allen Herman, Cannabis Science Inc., Chief Medical Officer (CMO).
About Cannabis Science, Inc.
Cannabis Science, Inc., takes advantage of its unique understanding of metabolic processes to provide novel treatment approaches to a number of illnesses for which current treatments and understanding remain unsatisfactory. Cannabinoids have an extensive history dating back thousands of years, and currently, there are a growing number of peer-reviewed scientific publications that document the underlying biochemical pathways that cannabinoids modulate. The Company works with leading experts in drug development, medicinal characterization, and clinical research to develop, produce, and commercialize novel therapeutic approaches for the treatment for illnesses caused by infections as well as for age-related illness. Our initial focus is on skin cancers, HIV/AIDS, and neurological conditions. The Company is proceeding with the research and development of its proprietary drugs as a part of this initial focus: CS-S/BCC-1, CS-TATI-1, and CS-NEURO-1, respectively.
Forward-Looking Statements
This Press Release includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Act of 1934. A statement containing words such as "anticipate," "seek," intend," "believe," "estimate," "expect," "project," "plan," or similar phrases may be deemed "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Some or all of the events or results anticipated by these forward-looking statements may not occur. Factors that could cause or contribute to such differences include the future U.S. and global economies, the impact of competition, and the Company's reliance on existing regulations regarding the use and development of cannabis-based drugs. Cannabis Science, Inc., does not undertake any duty nor does it intend to update the results of these forward-looking statements. Safe Harbor Statement. The Private Securities Litigation Reform Act of 1995 provides a 'safe harbor' for forward-looking statements. Certain of the statements contained herein, which are not historical facts are forward looking statements with respect to events, the occurrence of which involved risks and uncertainties. These forward- looking statements may be impacted, either positively or negatively, by various factors. Information concerning potential factors that could affect the company are detailed from time to time in the company's reports filed with the Securities and Exchange Commission.
IGXBio
Mr. Jim Laufenberg
President and CEO
Direct: 1.888.744.9246
info@igxbio.com
Cannabis Science, Inc.
Allen A. Herman, M.B., Ch.B., Ph.D.
Chief Medical Officer, SAB & IGAB Member
--04/06/16 -Cannabis Science Is Very Excited as the DEA Considers to Reschedule Marijuana/Cannabis With a Landmark Decision as Early as Mid-Year, 2016
COLORADO SPRINGS, CO -- (Marketwired) -- 04/06/16 -- Cannabis Science, Inc. (OTC PINK: CBIS), a U.S. company specializing in the development of cannabis-based medicines, today acknowledges and is very excited about the Landmark move with the Drug Enforcement Agency's (DEA) decision to review marijuana's federal drug classification as early as mid-2016. Rescheduling marijuana would ease restrictions on research across the country, while at the same time reducing penalties for marijuana offenses. Increased research capabilities could spur innovation and growth in the cannabis industry.
To review the Huffington Post article please click here to read the article in its entirety.
In a letter to the Senators; http://big.assets.huffingtonpost.com/dearesponse.pdf the Drug Enforcement Administration (DEA) is looking to decide on the reclassification of Marijuana by mid-year.
For years, marijuana has shared the "Schedule I" classification with heroin and LSD, drugs with much higher rates of death and hospitalization for users. This classification also specifies the drug has no "current accepted medical use". Cannabis Science, along with the masses, believe this has changed emphatically, based on the many ground-breaking university and private studies along with the ever growing long list of peer reviewed articles.
"We are very pleased to hear the DEA's decision to review marijuana's drug classification scheduling. It is clear to us and to so many others that the natural drug offers a host of health benefits and treatment properties. Cannabis Science will benefit extraordinarily as our research is already on the cutting edge, this Landmark move will open the industry in leaps and bounds," said Cannabis Science Inc. President, CEO & Co-Founder Raymond C. Dabney.
The DEA hopes to publish its decision in the first half of 2016. This decision is becoming increasingly important as more states decide to legalize cannabis for medicinal use. Nearly half of the U.S. states have already made such a decision, and a schedule change would have positive benefits for each of them.
About Cannabis Science, Inc.
Cannabis Science, Inc., takes advantage of its unique understanding of metabolic processes to provide novel treatment approaches to a number of illnesses for which current treatments and understanding remain unsatisfactory. Cannabinoids have an extensive history dating back thousands of years, and currently, there are a growing number of peer-reviewed scientific publications that document the underlying biochemical pathways that cannabinoids modulate. The Company works with leading experts in drug development, medicinal characterization, and clinical research to develop, produce, and commercialize novel therapeutic approaches for the treatment for illnesses caused by infections as well as for age-related illness. Our initial focus is on skin cancers, HIV/AIDS, and neurological conditions. The Company is proceeding with the research and development of its proprietary drugs as a part of this initial focus: CS-S/BCC-1, CS-TATI-1, and CS-NEURO-1, respectively.
Forward-Looking Statements
This Press Release includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Act of 1934. A statement containing words such as "anticipate," "seek," intend," "believe," "estimate," "expect," "project," "plan," or similar phrases may be deemed "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Some or all of the events or results anticipated by these forward-looking statements may not occur. Factors that could cause or contribute to such differences include the future U.S. and global economies, the impact of competition, and the Company's reliance on existing regulations regarding the use and development of cannabis-based drugs. Cannabis Science, Inc., does not undertake any duty nor does it intend to update the results of these forward-looking statements. Safe Harbor Statement. The Private Securities Litigation Reform Act of 1995 provides a 'safe harbor' for forward looking statements. Certain of the statements contained herein, which are not historical facts are forward looking statements with respect to events, the occurrence of which involved risks and uncertainties. These forward- looking statements may be impacted, either positively or negatively, by various factors. Information concerning potential factors that could affect the company are detailed from time to time in the company's reports filed with the Securities and Exchange Commission.
Cannabis Science Inc.
Teresa Misenheimer
Investor Relations
teresa@cannabisscience.com
Tel: 1-888-263-0832
Cannabis Science, Inc.
Mr. Raymond C. Dabney
President & CEO, Co-Founder
raymond.dabney@cannabisscience.com
Tel: 1-888-263-0832
Cannabis Science, Inc.
Mr. Robert Kane
Director & CFO
info@cannabisscience.com
Tel: 1-888-263-0832
Source: Cannabis Science, Inc.
I'm curious if they finally stop to make here again and again absolutely ridiculous....CBIS...
seems probably the right number to be ...
News out:04/04/16 The Cannabis Science 360,000 Sq. Ft., Drug Development Compound Educational, Medical Facilities, and Laboratory in Nevada Presents a Fully Licensed Opportunity for Additional 900,000 Sq. Ft., for Investment Tender to the Qualified Public
Cannabis Science New Toll Free Number 1-888-263-0832, for the General Public
COLORADO SPRINGS, CO -- (Marketwired) -- 04/04/16 -- Cannabis Science, Inc. (OTC PINK: CBIS), a U.S. company specializing in the development of cannabis-based medicines, today announced they have taken another step to improve the company's bottom line for United States cannabinoid pharmaceutical drug development programs. The Company also announced its new toll-free number 1-888-263-0832, as the President phone line has been inundated with cheer over the gifted share program. Please call the new number to ensure your information is documented. Once the Company website has been updated, a news release will point everyone in the right directions.
The Cannabis Science 360,000 Sq. Ft. Nevada pharmaceutical drug development compound is currently going through design phase; it will also include a University for higher educational curriculums, medicinal practice, and laboratory research.
The Nevada Compound presents an additional opportunity of over 900,000 Sq. Ft., for investment tender to the qualified public. The land is currently being partitioned into 1 Acre parcels that will allow for up to 36,000 Sq. Ft. each acre for cannabis cultivation, extract product development & research, fully licensed and state compliant.
The Company has now identified its next property development in the State of California, as it works through the paperwork; the Nevada development grows with more investors and entrepreneurs looking to capitalize and expand in the Nevada sector of the Cannabis Industry.
"This business model of building very large cannabis industry complexes has grown so fast for us it is literally spellbinding," stated President & CEO Raymond C. Dabney. "The opportunity presented itself and we seized the moment. That swift move has placed us in the formidable position to become one of the premier Companies providing education, medical facilities, and laboratories across the Country on some very large land parcels.
"The Nevada design phase is certainly underway and property lines and parcels are being completed. To be able to offer such a large amount of land coupled with the opportunity to other likeminded firms and individuals is a blessing on its own; to own a major piece of the operations is for Cannabis Science the landmark breakthrough we have been waiting for. This certainly changes the face of Cannabis Science.
"We have been negotiating with entrepreneurs and companies of various sizes and packages, on five-acre, three-acre, and one-acre parcels; at this rate we are confident filling these opportunities will not take long. For those that have the vision and believe that medical cannabis is the future, this partnership program enables them to be involved right now. The advancements in medical cannabis are virtually infinite. We are hearing from people that are looking for a ground floor opportunity as this industry is still in its infancy," concluded Dabney.
About Cannabis Science, Inc.
Cannabis Science, Inc., takes advantage of its unique understanding of metabolic processes to provide novel treatment approaches to a number of illnesses for which current treatments and understanding remain unsatisfactory. Cannabinoids have an extensive history dating back thousands of years, and currently, there are a growing number of peer-reviewed scientific publications that document the underlying biochemical pathways that cannabinoids modulate. The Company works with leading experts in drug development, medicinal characterization, and clinical research to develop, produce, and commercialize novel therapeutic approaches for the treatment for illnesses caused by infections as well as for age-related illness. Our initial focus is on skin cancers, HIV/AIDS, and neurological conditions. The Company is proceeding with the research and development of its proprietary drugs as a part of this initial focus: CS-S/BCC-1, CS-TATI-1, and CS-NEURO-1, respectively.
Forward-Looking Statements
This Press Release includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Act of 1934. A statement containing words such as "anticipate," "seek," intend," "believe," "estimate," "expect," "project," "plan," or similar phrases may be deemed "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Some or all of the events or results anticipated by these forward-looking statements may not occur. Factors that could cause or contribute to such differences include the future U.S. and global economies, the impact of competition, and the Company's reliance on existing regulations regarding the use and development of cannabis-based drugs. Cannabis Science, Inc., does not undertake any duty nor does it intend to update the results of these forward-looking statements. Safe Harbor Statement. The Private Securities Litigation Reform Act of 1995 provides a 'safe harbor' for forward looking statements. Certain of the statements contained herein, which are not historical facts are forward looking statements with respect to events, the occurrence of which involved risks and uncertainties. These forward- looking statements may be impacted, either positively or negatively, by various factors. Information concerning potential factors that could affect the company are detailed from time to time in the company's reports filed with the Securities and Exchange Commission.
Cannabis Science Inc.
Teresa Misenheimer
teresa@cannabisscience.com
Tel: 1-888-263-0832
Cannabis Science, Inc.
Mr. Raymond C. Dabney
President & CEO, Co-Founder
raymond.dabney@cannabisscience.com
Tel: 1-888-263-0832
Cannabis Science, Inc.
Mr. Robert Kane
Director & CFO
info@cannabisscience.com
Tel: 1-888-263-0832
Source: Cannabis Science, Inc.